Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Short term Debt (2021 - 2022)

Altimmune (ALT) has disclosed Short term Debt for 6 consecutive years, with $4.3 million as the latest value for Q1 2022.

  • Quarterly Short term Debt changed N/A to $4.3 million in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $4.3 million through Mar 2022, changed N/A year-over-year, with the annual reading at $6.1 million for FY2021, N/A changed from the prior year.
  • Short term Debt for Q1 2022 was $4.3 million at Altimmune, down from $6.1 million in the prior quarter.
  • The five-year high for Short term Debt was $6.1 million in Q4 2021, with the low at $4.3 million in Q1 2022.